Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cardiovascular Translational Research
Published in: Journal of Cardiovascular Translational Research 3/2013

01-06-2013

Platelet Function Testing in Patients with Acute Coronary Syndrome

Authors: Martin Orban, Dirk Sibbing

Published in: Journal of Cardiovascular Translational Research | Issue 3/2013

Login to get access

Abstract

In patients with an acute coronary syndrome (ACS), inhibition of the platelet P2Y12 receptor is standard of care. The shortcomings of the most commonly used P2Y12 receptor inhibitor clopidogrel—that is its delayed onset of action, its interindividual response variability, and the phenomenon of high on-treatment platelet reactivity—led to the development of more potent P2Y12 receptor inhibitors (prasugrel and ticagrelor) that proved their superiority in terms of reducing thrombotic events compared to clopidogrel. Available randomized studies that aimed at investigating the value of a personalized antiplatelet treatment regimen based on platelet function monitoring results were negative with regard to the possible benefits of monitoring but were all limited by mainly enrolling elective and stable patients with coronary artery disease. Thus, it still warrants further investigation if a tailored, platelet function guided, antiplatelet therapy in ACS patients with the available P2Y12 receptor inhibitors prasugrel, ticagrelor, and clopidogrel can lead to improved patients outcome.
Literature
1.
Schulz, C., & Massberg, S. (2012). Platelets in atherosclerosis and thrombosis. Handbook of Experimental Pharmacology., 210, 111–133.PubMedCrossRef
2.
Hamm, C. W., Bassand, J. P., Agewall, S., Bax, J., Boersma, E., Bueno, H., et al. (2011). ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 32, 2999–3054.PubMedCrossRef
3.
Wright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Jr., Ettinger, S. M., et al. (2011). 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. Journal of the American College of Cardiology, 57, e215–367.PubMedCrossRef
4.
Muller, I., Seyfarth, M., Rudiger, S., Wolf, B., Pogatsa-Murray, G., Schomig, A., et al. (2001). Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart, 85, 92–93.PubMedCrossRef
5.
Gurbel, P. A., Bliden, K. P., Hiatt, B. L., & O'Connor, C. M. (2003). Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation, 107, 2908–2913.PubMedCrossRef
6.
Serebruany, V. L., Steinhubl, S. R., Berger, P. B., Malinin, A. I., Bhatt, D. L., & Topol, E. J. (2005). Variability in platelet responsiveness to clopidogrel among 544 individuals. Journal of the American College of Cardiology, 45, 246–251.PubMedCrossRef
7.
Bonello, L., Tantry, U. S., Marcucci, R., Blindt, R., Angiolillo, D. J., Becker, R., et al. (2010). Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. Journal of the American College of Cardiology, 56, 919–933.PubMedCrossRef
8.
Sibbing, D., Braun, S., Morath, T., Mehilli, J., Vogt, W., Schomig, A., et al. (2009). Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. Journal of the American College of Cardiology, 53, 849–856.PubMedCrossRef
9.
Barragan, P., Bouvier, J. L., Roquebert, P. O., Macaluso, G., Commeau, P., Comet, B., et al. (2003). Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheterization and Cardiovascular Interventions, 59, 295–302.PubMedCrossRef
10.
Matetzky, S., Shenkman, B., Guetta, V., Shechter, M., Bienart, R., Goldenberg, I., et al. (2004). Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation, 109, 3171–3175.PubMedCrossRef
11.
Gurbel, P. A., Bliden, K. P., Guyer, K., Cho, P. W., Zaman, K. A., Kreutz, R. P., et al. (2005). Platelet reactivity in patients and recurrent events post-stenting: results of the prepare post-stenting study. Journal of the American College of Cardiology, 46, 1820–1826.PubMedCrossRef
12.
Hochholzer, W., Trenk, D., Bestehorn, H. P., Fischer, B., Valina, C. M., Ferenc, M., et al. (2006). Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. Journal of the American College of Cardiology, 48, 1742–1750.PubMedCrossRef
13.
Cuisset, T., Frere, C., Quilici, J., Morange, P. E., Nait-Saidi, L., Mielot, C., et al. (2007). High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thrombosis and Haemostasis, 97, 282–287.PubMed
14.
Buonamici, P., Marcucci, R., Migliorini, A., Gensini, G. F., Santini, A., Paniccia, R., et al. (2007). Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. Journal of the American College of Cardiology, 49, 2312–2317.PubMedCrossRef
15.
Bonello, L., Paganelli, F., Arpin-Bornet, M., Auquier, P., Sampol, J., Dignat-George, F., et al. (2007). Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. Journal of Thrombosis and Haemostasis, 5, 1630–1636.PubMedCrossRef
16.
Angiolillo, D. J., Bernardo, E., Sabate, M., Jimenez-Quevedo, P., Costa, M. A., Palazuelos, J., et al. (2007). Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. Journal of the American College of Cardiology, 50, 1541–1547.PubMedCrossRef
17.
Frere, C., Cuisset, T., Quilici, J., Camoin, L., Carvajal, J., Morange, P. E., et al. (2007). ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thrombosis and Haemostasis, 98, 838–843.PubMed
18.
Gori, A. M., Marcucci, R., Migliorini, A., Valenti, R., Moschi, G., Paniccia, R., et al. (2008). Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. Journal of the American College of Cardiology, 52, 734–739.PubMedCrossRef
19.
Price, M. J., Endemann, S., Gollapudi, R. R., Valencia, R., Stinis, C. T., Levisay, J. P., et al. (2008). Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. European Heart Journal, 29, 992–1000.PubMedCrossRef
20.
Cuisset, T., Cayla, G., Frere, C., Quilici, J., Poyet, R., Gaborit, B., et al. (2009). Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention, 5, 325–329.PubMedCrossRef
21.
Giusti, B., Gori, A. M., Marcucci, R., Saracini, C., Sestini, I., Paniccia, R., et al. (2009). Relation of cytochrome p450 2c19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. The American Journal of Cardiology, 103, 806–811.PubMedCrossRef
22.
Migliorini, A., Valenti, R., Marcucci, R., Parodi, G., Giuliani, G., Buonamici, P., et al. (2009). High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation, 120, 2214–2221.PubMedCrossRef
23.
Marcucci, R., Gori, A. M., Paniccia, R., Giusti, B., Valente, S., Giglioli, C., et al. (2009). Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation, 119, 237–242.PubMedCrossRef
24.
Sofi, F., Marcucci, R., Gori, A. M., Giusti, B., Abbate, R., & Gensini, G. F. (2010). Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thrombosis and Haemostasis, 103, 841–848.PubMedCrossRef
25.
Breet, N. J., van Werkum, J. W., Bouman, H. J., Kelder, J. C., Ruven, H. J., Bal, E. T., et al. (2010). Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. Journal of the American Medical Association, 303, 754–762.PubMedCrossRef
26.
Brar, S. S., ten Berg, J., Marcucci, R., Price, M. J., Valgimigli, M., Kim, H. S., et al. (2011). Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. Journal of the American College of Cardiology, 58, 1945–1954.PubMedCrossRef
27.
Parodi, G., Marcucci, R., Valenti, R., Gori, A. M., Migliorini, A., Giusti, B., et al. (2011). High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. The Journal of the American Medical Association, 306, 1215–1223.CrossRef
28.
Sibbing, D., Bernlochner, I., Schulz, S., Massberg, S., Schomig, A., Mehilli, J., et al. (2012). Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients: ISAR-REACT-4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. Journal of the American College Cardiology, 60(5), 369–377.CrossRef
29.
Stone, G. W. (2011) ADAPT-DES: a large-scale, prospective, multicenter registry examining the relationship of platelet responsiveness to stent thrombosis after DES implantation. Transcatheter cardiovascular therapeutics. San Francisco, November 9, 2011.
30.
Stone, G.W. (2012). ADAPT-DES: a large-scale, prospective, multicenter registry examining the relationship of platelet responsiveness to stent thrombosis after DES implantation. Transcatheter cardiovascular therapeutics. San Francisco, October 25, 2012.
31.
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., et al. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine, 357, 2001–2015.PubMedCrossRef
32.
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., et al. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine, 361, 1045–1057.PubMedCrossRef
33.
Sibbing, D., Schulz, S., Braun, S., Morath, T., Stegherr, J., Mehilli, J., et al. (2010). Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. Journal of Thrombosis and Haemostasis, 8, 250–256.PubMedCrossRef
34.
Serebruany, V., Rao, S. V., Silva, M. A., Donovan, J. L., Kannan, A. O., Makarov, L., et al. (2010). Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. European Heart Journal, 31, 227–235.PubMedCrossRef
35.
Campo, G., Parrinello, G., Ferraresi, P., Lunghi, B., Tebaldi, M., Miccoli, M., et al. (2011). Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. Journal of the American College of Cardiology, 57, 2474–2483.PubMedCrossRef
36.
Bonello, L., Mancini, J., Pansieri, M., Maillard, L., Rossi, P., Collet, F., et al. (2012). Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. Journal of Thrombosis and Haemostasis, 10, 1999–2005.PubMedCrossRef
37.
Kastrati, A., Neumann, F. J., Schulz, S., Massberg, S., Byrne, R. A., Ferenc, M., et al. (2011). Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. The New England Journal of Medicine, 365, 1980–1989.PubMedCrossRef
38.
Price, M. J. (2010). Standard versus high-dose clopidogrel according to platelet function testing after PCI: results of the GRAVITAS trial. Circulation, 122, 2215–2226.CrossRef
39.
Trenk, D., Stone, G. W., Gawaz, M., Kastrati, A., Angiolillo, D. J., Muller, U., et al. (2012). A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy with Prasugrel) study. Journal of the American College of Cardiology, 59, 2159–2164.PubMedCrossRef
40.
Collet, J. P., Cuisset, T., Range, G., Cayla, G., Elhadad, S., Pouillot, C., et al. (2012). Bedside monitoring to adjust antiplatelet therapy for coronary stenting. The New England Journal of Medicine, 367, 2100–2109.PubMedCrossRef
41.
Bonello, L., Pansieri, M., Mancini, J., Bonello, R., Maillard, L., Barnay, P., et al. (2011). High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. Journal of the American College of Cardiology, 58, 467–473.PubMedCrossRef
42.
Aradi, D., Kuliczkowski, W., Atar, D., & Serebruany, V. L. (2012). Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thrombosis and Haemostasis, 107, 338–345.PubMedCrossRef
43.
Bernlochner I., Mayer K., Morath T., Orban M., Schulz S., Schömig A., et al. (2013). Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. Thrombosis and Haemostasis. doi: 10.1160/TH12-08-0552
44.
Wrishko, R. E., Ernest, C. S., 2nd, Small, D. S., Li, Y. G., Weerakkody, G. J., Riesmeyer, J. R., et al. (2009). Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. Journal of Clinical Pharmacology, 49, 984–998.PubMedCrossRef
45.
Cuisset, T., Loosveld, M., Morange, P. E., Quilici, J., Moro, P. J., Saut, N., et al. (2012). Cyp2c19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. JACC Cardiovascular Interventions, 5, 1280–1287.PubMedCrossRef
46.
Parodi, G., Bellandi, B., Venditti, F., Carrabba, N., Valenti, R., Migliorini, A., et al. (2012). Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. The American Journal of Cardiology, 109, 214–218.PubMedCrossRef
47.
Alexopoulos, D., Galati, A., Xanthopoulou, I., Mavronasiou, E., Kassimis, G., Theodoropoulos, K. C., et al. (2012). Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. Journal of the American College of Cardiology, 60, 193–199.PubMedCrossRef
48.
Alexopoulos, D., Xanthopoulou, I., Gkizas, V., Kassimis, G., Theodoropoulos, K. C., Makris, G., et al. (2012). Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST elevation myocardial infarction. Circulation Cardiovascular Intervention, 5(6), 797–804.CrossRef
49.
Werdan, K., Russ, M., Buerke, M., Delle-Karth, G., Geppert, A., Schondube, F. A., et al. (2012). Cardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment: a German-Austrian S3 Guideline. Deutsches Arzteblatt international, 109, 343–351.PubMed
50.
Osmancik, P., Jirmar, R., Hulikova, K., Peroutka, Z., Pompachova, A., Motovska, Z., et al. (2010). A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheterization and Cardiovascular Interventions, 75, 158–166.PubMedCrossRef
51.
Orban, M., Byrne, R. A., Hausleiter, J., Laugwitz, K. L., & Sibbing, D. (2011). Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock. Thrombosis and Haemostasis, 106.
52.
Orban, M., Riegger, J., Joner, M., Tada, T., Okrojek, R., Hausleiter, J., et al. (2012). Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. Platelets., 23(5), 395–398.PubMedCrossRef
53.
Cuisset, T., Frere, C., Quilici, J., Barbou, F., Morange, P. E., Hovasse, T., et al. (2006). High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. Journal of Thrombosis and Haemostasis, 4, 542–549.PubMedCrossRef
54.
Geisler, T., Kapp, M., Gohring-Frischholz, K., Daub, K., Dosch, C., Bigalke, B., et al. (2008). Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart, 94, 743–747.PubMedCrossRef
Metadata
Title
Platelet Function Testing in Patients with Acute Coronary Syndrome
Authors
Martin Orban
Dirk Sibbing
Publication date
01-06-2013
Publisher
Springer US
Published in
Journal of Cardiovascular Translational Research / Issue 3/2013
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-013-9450-7

Other articles of this Issue 3/2013

Journal of Cardiovascular Translational Research 3/2013 Go to the issue

OriginalPaper

Pharmaco-mechanic Antithrombotic Strategies to Reperfusion of the Infarct-Related Artery in Patients with ST-Elevation Acute Myocardial Infarctions

OriginalPaper

von Willebrand Factor Inhibition Improves Endothelial Function in Patients with Stable Angina

OriginalPaper

St. John’s Wort in Patients Non-responders to Clopidogrel Undergoing Percutaneous Coronary Intervention: a Single-Center Randomized Open-Label Trial (St. John’s Trial)

OriginalPaper

Novel Anti-platelet Agents: Focus on Thrombin Receptor Antagonists

OriginalPaper

Beneficial Cardiac Effects of Caloric Restriction Are Lost with Age in a Murine Model of Obesity

OriginalPaper

Influence of Platelet Reactivity on Clinical Outcome of Patients with Stable Coronary Artery Disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits